title: Suppression of polyglutamine toxicity by the yeast Sup35 prion domain in Drosophila.
abstract: The propensity of proteins to form beta-sheet-rich amyloid fibrils is related to a variety of biological phenomena, including a number of human neurodegenerative diseases and prions. A subset of amyloidogenic proteins forms amyloid fibrils through glutamine/asparagine (Q/N)-rich domains, such as pathogenic polyglutamine (poly(Q)) proteins involved in neurodegenerative disease, as well as yeast prions. In the former, the propensity of an expanded poly(Q) tract to abnormally fold confers toxicity on the respective protein, leading to neuronal dysfunction. In the latter, Q/N-rich prion domains mediate protein aggregation important for epigenetic regulation. Here, we investigated the relationship between the pathogenic ataxin-3 protein of the human disease spinocerebellar ataxia type 3 (SCA3) and the yeast prion Sup35, using Drosophila as a model system. We found that the capacity of the Sup35 prion domain to mediate protein aggregation is conserved in Drosophila. Although select yeast prions enhance poly(Q) toxicity in yeast, the Sup35N prion domain suppressed poly(Q) toxicity in the fly. Suppression required the oligopeptide repeat of the Sup35N prion domain, which is critical for prion properties in yeast. These results suggest a trans effect of prion domains on pathogenic poly(Q) disease proteins in a multicellular environment and raise the possibility that Drosophila may allow studies of prion mechanisms.
authors.affiliation: Department of Biology, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, PA 19104-6018, USA.
authors.forename: Ling-Bo
authors.initials: LB
authors.lastname: Li
authors.forename: Kexiang
authors.initials: K
authors.lastname: Xu
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Bonini
mesh_terms: D020816:Amino Acid Motifs; D000818:Animals; D000067699:Ataxin-3; D002460:Cell Line; D004331:Drosophila melanogaster / Q000378:metabolism; D044127:Epigenesis, Genetic; D005656:Fungal Proteins / Q000737:chemistry; D005786:Gene Expression Regulation; D006801:Humans; D008954:Models, Biological; D009419:Nerve Tissue Proteins / Q000096:biosynthesis; D009687:Nuclear Proteins / Q000096:biosynthesis; D010454:Peptide Termination Factors; D010455:Peptides / Q000378:metabolism*; D011328:Prions / Q000737:chemistry* / Q000502:physiology; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012097:Repressor Proteins / Q000096:biosynthesis; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D029701:Saccharomyces cerevisiae Proteins / Q000737:chemistry* / Q000502:physiology*
chemical_list: D005656:Fungal Proteins; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D010454:Peptide Termination Factors; D010455:Peptides; D011328:Prions; D012097:Repressor Proteins; C068068:SUP35 protein, S cerevisiae; D029701:Saccharomyces cerevisiae Proteins; C097188:polyglutamine; C092341:ATXN3 protein, human; D000067699:Ataxin-3